Palivizumab prophylaxis in ‘late preterm’ newborns

References

• Kirby RS. Late preterm birth and neonatal outcome: is 37 weeks' gestation a threshold level or a road marker on the highway of perinatal risk?Birth 2010;37:169–171.
   PubMed Web of Science ®Google Scholar
• AAP, ACOG. Standard terminology for reporting of reproductive health statistics in the United States. Guidelines for Perinatal Care (5th edition, Appendix E)Elk Grove, ILAmerican Academy of Pediatrics and American College of Obstetricians and Gynecologists2002. pp. 377–394.
   Google Scholar
• Heron M, Sutton PD, Xu J, Ventura SJ, Strobino DM, Guyer B. Annual summary of vital statistics: 2007. Pediatrics 2010;125:4–15.
   PubMed Web of Science ®Google Scholar
• Bettegowda VR, Dias T, Davidoff MJ, Damus K, Callaghan WM, Petrini JR. The relationship between cesarean delivery and gestational age among US singleton births. Clin Perinatol 2008;35:309–323.
   PubMed Web of Science ®Google Scholar
• Stephens BE, Vohr BR. Neurodevelopmental outcome of the premature infant. Pediatr Clin North Am 2009;56:631–646.
   PubMed Web of Science ®Google Scholar
• Darcy AE. Complications of the late preterm infant. J Perinat Neonat Nurs 2009;23:78–86.
   PubMed Web of Science ®Google Scholar
• Mathews TJ, MacDorman MF. Infant mortality statistics from the 2005 period linked birth/infant death data set. Natl Vital Stat Rep 2008;57:1–32.
   PubMedGoogle Scholar
• McLaurin KK, Hall CB, Jackson EA, Owens OV, Mahadevia PJ. Persistence of morbidity and cost differences between late-preterm and term infants during the first year of life. Pediatrics 2009;123:653–659.
   PubMed Web of Science ®Google Scholar
• Shapiro-Mendoza CK, Tomashek KM, Kotelchuck M, Barfield W, Nannini A, Weiss J, Declercq E. Effect of late-preterm birth and maternal medical conditions on newborn morbidity risk. Pediatrics 2008;121:e223–e32.
   PubMed Web of Science ®Google Scholar
• Doyle LW, Cheung MM, Ford GW, Olinsky A, Davis NM, Callanan C. Birth weight <1501 g and respiratory health at age 14. Arch Dis Child 2001;84:40–44.
   PubMed Web of Science ®Google Scholar
• Moss TJ. Respiratory consequences of preterm birth. Clin Exp Pharmacol Physiol 2006;33:280–284.
   PubMed Web of Science ®Google Scholar
• Langston C, Kida K, Reed M, Thurlbeck WM. Human lung growth in late gestation and in the neonate. Am Rev Respir Dis 1984;129:607–613.
   PubMed Web of Science ®Google Scholar
• Friedrich L, Stein RT, Pitrez PMC, Corso AL, Jones MH. Reduced lung function in healthy preterm infants in the first months of life. Am J Respir Crit Care Med 2006;173:442–447.
   PubMed Web of Science ®Google Scholar
• Galdes-Sebaldt M, Sheller JR, Grogaard J, Stahlman M. Prematurity is associated with abnormal airway function in childhood. Pediatr Pulmonol 1989;7:259–264.
   PubMed Web of Science ®Google Scholar
• Wang ML, Dorer DJ, Fleming MO, Catlin EA. Clinical outcomes of near-term infants. Pediatrics 2004;114:372–376.
   PubMed Web of Science ®Google Scholar
• Mussi-Pinhata M, Gonçalves AL. Serum immunoglobulin levels and incidence of infection during the first year of life in full-term and preterm infants. J Trop Pediatr 1989;35:147–153.
   PubMed Web of Science ®Google Scholar
• Bont L, Kimpen JL. Immunological mechanisms of severe respiratory syncytial virus bronchiolitis. Intensive Care Med 2002;28:616–621.
   PubMed Web of Science ®Google Scholar
• Willson DF, Landrigan CP, Horn SD, Smouht RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003;143:S142–S149.
   PubMed Web of Science ®Google Scholar
• Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;143:S133–S141.
   PubMed Web of Science ®Google Scholar
• Meissner H, Welliver R, Chartrand S, Law B, Weisman L, Dorkin HL, Rodriguez WJ. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999;18:223–231.
   PubMed Web of Science ®Google Scholar
• No authors listed. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531–537.
   Web of Science ®Google Scholar
• Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003;35:484–489.
   PubMed Web of Science ®Google Scholar
• Figueras AJ, Quero J, Domenech E. Comite de Estandares de la Sociedad Espanola de Neonatologia. Recommendations for the prevention of respiratory syncytial virus infection. An Pediatr (Barc) 2005;63:357–362.
   PubMedGoogle Scholar
• Rondini G, Macagno F, Barberi I. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta Neonatologica 2004;1:1–11.
   Google Scholar
• Deutsche Gesellschaft für Pädiatrische Infektiologie (DGPI) Stellungnahme zur Prophylaxe von schweren RSVErkrankungen bei Risikokindern mit Palivizumab; 2006. Available at http://www.dgpi.de/pdf/Leitlinie_Palivizumab_27Okt2006.pdf (accessed December 2006).
   Google Scholar
• American Academy of Pediatrics. Respiratory Syncytial Virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics 2009:560–569.
   Google Scholar
• Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UDL, Chezzi1 C; on behalf of the ‘‘Osservatorio VRS Study’’ Group. Four-year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the ‘‘Osservatorio VRS’’ Study (2000–2004). The New Microbiologica 2006;29:35–43.
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalisation in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J 2004;23:815–820.
   PubMed Web of Science ®Google Scholar
• Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalisation for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806–814.
   PubMed Web of Science ®Google Scholar
• Simoes EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003;143:S118–S126.
   PubMed Web of Science ®Google Scholar
• Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, Liese JG. The risk of respiratory syncytial virus-related hospitalisations in preterm infants of 29 to 35 weeks gestational age. Pediatr Infect Dis J 2006;25:1188–1190.
   PubMed Web of Science ®Google Scholar
• Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, Silvestri M, Pistorio A, Chezzi C; Osservatorio RSV Study Group. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007;166:1267–1272.
   PubMed Web of Science ®Google Scholar
• Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J; European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78–87.
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, Mitchell I, Aloy JF, Pedraz C, Michaliszyn AF. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471–480.
   PubMed Web of Science ®Google Scholar
• Paes B, Steele S, Janes M, Pinelli J. Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009;25:1585–1591.
   PubMed Web of Science ®Google Scholar